AUAUniversity

Highlights from AUA2025: Advances in NMIBC (2025) CME Available: https://auau.auanet.org/node/43167 At the conclusion of this CME activity, participants will be able to: 1. Recognize recent developments in the management of NMIBC. 2. Evaluate new and emerging therapies for NMIBC, such as novel intravesical agents and immunotherapies, their mechanism of action and related adverse events. 3. Employ current management approaches for NMIBC. 4. Utilize risk stratification to guide treatment decisions for NMIBC patients. 5. Implement diagnostic techniques for NMIBC, including cystoscopy, urine cytology, biomarkers, and advanced imaging modalities. This educational activity is supported by independent educational grants from: Merck & Co., Inc. ImmunityBio, Inc.

AUA Guidelines: Microhematuria Co-Hosts: Daniel A. Barocas, MD, MPH & Stephen Boorjian, MD Microhematuria: AUA/SUFU Guideline (2025) Barocas DA, Lotan Y, Matulewicz RS, Raman JD, Westerman ME, Kirkby E, Pak L, Souter L. Updates to Microhematuria: AUA/SUFU Guideline (2025). J Urol. 0(0). doi: 10.1097/JU.0000000000004490. https://www.auajournals.org/doi/abs/10.1097/JU.0000000000004490

AUA2025: Embracing Multi-Disciplinary Care for Advanced Prostate Cancer: A Case-Based Update 2025 CME Available: https://auau.auanet.org/node/42997 At the conclusion of this activity, participants will be able to: 1. Initial Management of Metastatic Prostate Cancer: Evaluate and treat a patient with new diagnosed M1 prostate cancer with androgen deprivation therapy (ADT) plus be skilled to offer novel oral antiandrogens. Furthermore, to recognize high-volume new M1 prostate cancer so as to be able to partner with GU medical oncologist for docetaxel chemotherapy in a multidisciplinary team. 2. Non-Metastatic Castrate Resistant Prostate Cancer (M0 CRPC): The learner will be skilled to diagnose M0 CRPC and be able to educate patients about using either enzalutamide or apalutamide or darolutamide added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these three oral agents and to educate patients about side-effects and toxicities. Finally, understand the pros and cons of PSMA PET scan imaging in further staging in this disease Non-metastatic Castrate-Resistant Prostate Cancer (M0 CRPC): Diagnose M0 CRPC and be able to educate patients about using novel oral antiandrogens added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these novel oral agents and to educate patients about side effects and toxicities. Finally, understand the pros and cons of PSMA PET scan imaging in further staging in this disease state. 3. Metastatic Castrate-Resistant Prostate Cancer (M1 CRPC): Describe and have a working knowledge of the latest phase III RCT results for new therapies in M1 CRPC and be able to educate their patients on treatment options and participate in a multidisciplinary team caring for men with this disease state of far-advanced prostate cancer. 4. Describe that advanced prostate cancer is a complex group of disease states with an ever-changing therapeutic landscape and for providers and teams to embrace the multi-disciplinary nature of care for our patients. 5. Identify the molecular and molecular genetic underpinnings of advanced prostate cancer and recognize the future will be based on a more personalized therapy landscape including PARP inhibition, immune checkpoint agents, and novel AR targeted agents emerging in 2025 and beyond.

AUA2025: Non-Muscle Invasive Bladder Cancer Treatment Dilemmas: The Cases You Face and How Best to Treat Them CME Available: https://auau.auanet.org/node/43041 At the conclusion of this activity, participants will be able to: 1. Confidently apply updated guidelines to the care of patients with non-muscle-invasive bladder cancer. 2. Risk-stratify patients with non muscle- invasive bladder cancer. 3. Adapt treatment choices depending on risk of disease, including consideration to the availability of bacillus Calmette-Guérin. 4. Counsel and manage patients with bacillus Calmette-Guérin-unresponsive non muscle-invasive bladder cancer, including treatment selection with newly approved agents for BCG-unresponsive disease. 5. Individualize patient surveillance according to risk stratification. 6. Evaluate available urinary bladder cancer biomarkers and where to potentially utilize them in practice to inform management. ACKNOWLEDGEMENTS This educational activity is supported by an independent educational grants from: Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

AUA2025: Integration of Biomarkers, MRI and PSMA PET Imaging Into the Management of Prostate Cancer CME Available: https://auau.auanet.org/node/43069 At the conclusion of this CME activity, participants will be able to: 1. Evaluate recent advances in biomarkers and molecular imaging technologies and their role in improving the accuracy of prostate cancer staging, and treatment monitoring. 2. Identify the clinical scenario in which PSMA PET/CT is most helpful to identify the localization and extent of locoregional or systemic metastatic disease. 3. Identify the pitfalls of false-positive and false-negative PSMA PET/CT findings. 4. Apply the findings of PSMA PET/CT for the best individual therapeutic approach. 5. Identify patients with radiorecurrent organ-confined prostate cancer. ACKNOWLEDGEMENTS Support provided by independent educational grants from: Blue Earth Diagnostics, Inc. Lantheus Medical Imaging Novartis Pharmaceuticals Corporation

AUA2025: PARP-Inhibitor Combination Treatments for the Urologic Care Team CME Available: https://auau.auanet.org/node/42822 At the conclusion of this CME activity, participants will be able to: 1. Apply the mechanism of action of PARP inhibitors and the rationale for using them in patients with advanced prostate cancer. 2. Recognize the role and importance of genetic testing in patients with mCRPC and the implications of germline mutations on response to therapy. 3. Identify best practices and utilize available guidelines for patients with mCRPC to optimize treatment success and oncologic outcomes. 4. Recognize when to use PARP inhibitors as monotherapy, the rationale and indications for combination therapy, and appropriate treatment sequencing. 5. Successfully counsel patients on the possible adverse events associated with PARP inhibitor therapies alone or in combination. ACKOWLEDGEMENTS Support provided by independent educational grants from: AstraZeneca Merck & Co., Inc.

Live from AUA2025: Advances in ADT Program CME Available: https://auau.auanet.org/content/LiveFromAUA2025#group-tabs-node-course-default1 At the conclusion of this CME activity, participants will be able to: 1. Employ the latest AUA and NCCN guidelines (Version 1.2025) related to Androgen Deprivation Therapy (ADT) into practice 2. Evaluate clinical outcomes, efficacy, and safety profiles of different types of ADT including oral and parenteral LHRH agonists and GnRH receptor antagonists in different treatment settings. 3. Compare testosterone recovery, treatment efficacy, safety profiles, and patient preferences between different modalities of ADT. 4. Recognize common side effects associated with different types of ADT and its combination therapies as well as strategies to mitigate these adverse effects to improve patient outcomes. 5. Implement a multi-disciplinary approach in managing advanced prostate cancer with ADT. 6. Evaluate the future directions and ongoing research that may impact the use of ADT in clinical practice.

AUA2025: Sexual Medicine Society of North America Meeting Cohost: Landon Trost, MD Outline: Segment #1: What is the Sexual Medicine Society of North America and what unique value does it bring to its members and the broader field of urology. Segment #2: For the AUA2025 meeting, what can you tell us about the agenda and what the audience can expect from the meeting? Segment #3: What are the main clinical areas being highlighted at the SMSNA meeting at AUA2025? Segment #4: What is new or exciting on the horizon in your sub-specialty? Segment #5: What final message what you like to leave with listeners related to your sub-specialty and/or the SMSNA meeting at AUA2025?

AUA2025: Society of Urological Robotic Surgeons Meeting Cohost: Michael D. Stifelman, MD Outline: Segment #1: What is the Society of Urological Robotic Surgeons and what unique value does it bring to its members and the broader field of urology. Segment #2: For the AUA2025 meeting, what can you tell us about the agenda and what the audience can expect from the meeting? Segment #3: What are the main clinical areas being highlighted at the SURS meeting at AUA2025? Segment #4: What is new or exciting on the horizon in your sub-specialty? Segment #5: What final message what you like to leave with listeners related to your sub-specialty and/or the SURS meeting at AUA2025?

AUA2025: Focal Therapy Society Meeting Cohost: Rafael Sanchez-Salas, MD Outline: Segment #1: What is the Focal Therapy Society and what unique value does it bring to its members and the broader field of urology. Segment #2: For the AUA2025 meeting, what can you tell us about the agenda and what the audience can expect from the meeting? Segment #3: What are the main clinical areas being highlighted at the FTS meeting at AUA2025? Segment #4: What is new or exciting on the horizon in your sub-specialty? Segment #5: What final message what you like to leave with listeners related to your sub-specialty and/or the FTS meeting at AUA2025?

Update Series 2025 Lesson 9: Congenitalism: Transitioning Patients with Congenital Urological Anomalies from the Pediatric to the Adult Care Setting Update Series 2025 Lesson 9: Congenitalism: Transitioning Patients with Congenital Urological Anomalies from the Pediatric to the Adult Care Setting Now in its 44th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update25

AUA2025: Masterclass: Renal Access and Interventions (2025) Cohost: Rob Sweet, MD, FACS, MAMSE and Thomas Chi, MD, MBA Tune in to hear straight from the experts about what you can expect from our NEWLY DESIGNED Full Day Hands-on Skills Trainings at AUA2025! In this episode, Drs. Thomas Chi and Robert Sweet discuss Masterclass: Renal Access and Interventions, an all new interactive training offering skills in percutaneous renal access and image-guided renal interventions. Early Bird deadline for Hands-on Skills trainings has been EXTENDED - ends March 24. Spaces are limited – Register now!

Hereditary Kidney Cancer Syndromes CME Available: https://auau.auanet.org/node/41772 ACKNOWLEDGEMENTS: Support provided by an independent educational grant from:  Merck & Co., Inc.  LEARNING OBJECTIVES: At the conclusion of this activity, participants should be able to: 1. Select patients who should undergo genetic testing to identify hereditary kidney cancer syndromes based on appropriate criteria, including family history and clinical presentation. 2. Implement strategies to address ethical concerns related to genetic testing, such as patient consent, confidentiality, and the potential impact on family members. 3. Discuss VHL syndrome, including its genetic basis, inheritance pattern, and associated tumors. 4. Properly diagnose and manage VHL syndrome in clinical practice based on knowledge of novel therapeutic strategies. 5. Utilize a multidisciplinary approach consisting of urologists, oncologists, geneticists and nephrologists when managing hereditary kidney cancer syndromes.

AUA2025: Fundamentals of Prostate MRI and Transperineal Interventions (2025) Cohost: Arvin K. George, MD and James Wysock, MD, MSc Tune in to hear straight from the experts about what you can expect from our NEWLY DESIGNED Full Day Hands-on Skills Trainings at AUA2025! In this episode, Dr. Arvin K. George and Dr. James Wysock discuss optimizing diagnosis of clinically significant prostate cancer along with a preview of what practicing urologists will gain from attending Fundamentals of Prostate MRI and Transperinal Interventions. Among the skillsets of MRI interpretation, segmentation, fusion-guided transperineal prostate biopsy, and transperineal spacer techniques, attendees also receive access to a library of on-demand virtual didactics straight from the experts! Early Bird deadline for Hands-on Skills trainings ends March 7. Spaces are limited – Register now! https://www.auanet.org/AUA2025/register/hands-on-skills-trainings Outline: Segment #1: The Changing Landscape of Prostate Cancer Diagnostics Segment #2: Why Transperineal Biopsy? Segment #3: What Participants Will Learn - MRI Segment #4: What Participants Will Learn – Transperineal Techniques Segment #5: Why you should attend this course

Recognition and Management of Complications Following Gender Affirming Surgery Co-Host: Laura Douglass, MD Outline: Segment #1 Topic: Why is this important for ALL urologists to know? Segment #2 Topic: Introduction to Gender Affirming Surgery (GAS) Segment #3 Topic: Emergency/ED consultations vs. Outpatient/clinic consultations Resources: - Hanley K, Wittenberg H, Gurjala D, Safir MH, Chen EH. Caring for Transgender Patients: Complications of Gender-Affirming Genital Surgeries. Ann Emerg Med. 2021 Sep;78(3):409-415. - Krakowsky Y, Shah G, Nguyen AV, Kavanagh AG, Potter E, Remondini T, Goldsher YW, Millman A. Gender-affirming care in urology: emergency care of the gender-affirming surgical patient-what the primary urologist needs to know. BJU Int. 2024 Feb;133(2):124-131. doi: 10.1111/bju.16249. Epub 2023 Dec 14. PMID: 38060336. - Mann RA, Kasabwala K, Kim N, Pariser JJ. The Management of Complications of Feminizing Gender Affirming Genital Surgery. Urology. 2021 Jun;152:67-73. doi: 10.1016/j.urology.2021.01.031. Epub 2021 Jan 23. PMID: 33493512. - Maffucci F, Clark J, Jun M, Douglass L. A Urologist's Guide to Caring for Transgender and Gender Diverse Patients. Urol Clin North Am. 2023 Nov;50(4):577-585. doi: 10.1016/j.ucl.2023.06.020. Epub 2023 Aug 9. PMID: 37775216. - Nikolavsky D, Hughes M, Zhao LC. Urologic Complications After Phalloplasty or Metoidioplasty. Clin Plast Surg. 2018 Jul;45(3):425-435. doi: 10.1016/j.cps.2018.03.013. PMID: 29908632.

AUA Guidelines: Diagnosis and Treatment of Infertility in Men Co-Host: Robert E. Brannigan, MD Outline: Segment #1 Topic: New Table 1 Reviewing “Common Terms” in Semen Analysis and Update to the WHO Semen Analysis Reference Ranges Segment #2 Update to the WHO Semen Analysis Reference Ranges Segment #3 Topic: Y Chromosome Microdeletion Testing Change in Testing Guidance Segment #4 Topic: Pelvic MRI imaging is an option for men with suspected ejaculatory duct obstruction Segment #5 Topic: For couples with recurrent pregnancy loss, clinicians should evaluate the male partner with karyotype (Expert Opinion) and sperm DNA fragmentation Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline Brannigan RE, Hermanson L, Kaczmarek J, Kim SK, Kirkby E, Tanrikut C. Updates to male infertility: AUA/ASRM guideline (2024). J Urol. Published online August 15, 2024. doi:10.1097/JU.0000000000004180. https://www.auajournals.org/doi/10.1097/JU.0000000000004180

AUA Guidelines: Diagnosis And Treatment Of Idiopathic Overactive Bladder Co-Host: Anne Pelletier Cameron, MD, FRCSC, URPS Segment #1: Is this an update to the prior Guideline? Segment #2: What is new in the Diagnosis, ntitial Assessment and Initial Management of OAB? Segment#3: What does the Guideline say about Oral Medication? Segment #4: What's new in minimally invasive prodcedures Segment #5: UDS and Cystoscopy Segment #6: What is new and exciting on the horizion for OAB Segment #7: Where to start and the most impactpact research in this area The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol. Published online April 23, 2024. doi:10.1097/JU.0000000000003985. https://www.auajournals.org/doi/10.1097/JU.0000000000003985

AUA Guidelines: Treatment Of Non - Metastatic Muscle - Invasive Bladder Cancer Guest: Jeffrey M Holzbeierlein, MD Outline: Segment #1: Guideline Statement 9-Patients who have not received cisplatin-based NAC and have pT3-4 and/or N= disease at cystectomy should receive adjuvant cisplatin based chemotherapy or adjuvant immunotherapy. Segment #2: Guideline Statement 11-When performing a cystectomy in males the bladder, prostate cand seminal vesicles should be removed (no change) but in females clinicians should consider removal of adjacent reproductive organs based on individual disease characteristics and need to obtain negative margins. Organ sparing procedures in females should be considered based on disease location and characteristics on an individual basis. Segment #3: Guideline Statement 20-When performing bilateral pelvic lymphadenectomy , clinicians should remove, at a minimum, the external and internal iliac and obturator lymph nodes (standard lymphadenectomy). Segment #4: Future Directions Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline Holzbeierlein J, Bixler BR, Buckley DI, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/SUO guideline (2017; amended 2020, 2024). J Urol. Published online April 25, 2024. doi:10.1097/JU.0000000000003981 https://www.auajournals.org/doi/10.1097/JU.0000000000003981

Biomarkers and Molecular Imaging for Prostate Cancer CME Available: auau.auanet.org/node/41727 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Explain the principles of molecular imaging and its application in prostate cancer, including techniques such as PET, MRI, and novel radiotracers. 2. Evaluate recent advances in molecular imaging technologies and their role in improving the accuracy of prostate cancer diagnosis, staging, and treatment monitoring. 3. Define and classify different types of biomarkers relevant to prostate cancer, including diagnostic, prognostic, and predictive biomarkers.

Appropriate Use of Genetic Testing (who, what, when and how?) CME Available: auau.auanet.org/node/41734 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Identify the patient populations that should be considered for genetic testing in prostate cancer, based on family history, personal risk factors, and clinical indications. 2. Integrate genetic testing into clinical practice for prostate cancer, including developing workflows, referral processes, and multidisciplinary collaboration. 3. Utilize genetic test results to inform personalized treatment plans for prostate cancer patients, including targeted therapies and risk reducing strategies.

Treatment Intensification in Metastatic HSPC CME Available: https://auau.auanet.org/node/41733 ACKNOWLEDGEMENTS: Support provided by independent educational grants from:  Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Explain the rationale behind treatment intensification in metastatic hormone sensitive prostate cancer (mHSPC), based on its pathophysiology.  2. Analyze the rationale and clinical evidence supporting treatment intensification in mHSPC, including potential benefits and risks.  3. Select appropriate patients for treatment intensification, considering factors such as disease burden, patient comorbidities, and individual risk profiles.

Sequencing Of Agents CME Available: auau.auanet.org/node/41735 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Review the latest evidence and clinical guidelines that inform the sequencing of therapeutic agents in metastatic prostate cancer, including data from key clinical trials. 3. Implement strategies for managing and overcoming resistance to therapy in metastatic prostate cancer, considering the role of sequencing in delaying resistance. 4. Apply best practices for monitoring treatment response and disease progression in patients undergoing therapy, and adjust sequencing strategies based on these observations.

Non-Muscle Invasive Bladder Cancer: Expert Guidance for Urologists CME Available: https://auau.auanet.org/node/41961 After participating in this CME activity, participants will be able to: 1. Assess the risk stratification of low, intermediate, and high risk NMIBC patients to appropriately guide treatment decisions. 2. Employ diagnostic techniques for NMIBC, including cystoscopy, urine cytology, biomarkers, and advanced imaging modalities. 3. Tailor treatment strategies based on individual patient characteristics and tumor biology to highlight the potential of personalized medicine in improving the management of NMIBC. 4. Identify new and emerging therapies for NMIBC, such as novel intravesical agents and immunotherapies. 5. Properly manage adverse events associated with NMIBC treatment. Acknowledgements Support provided by an independent educational grant from: ImmunityBio, Inc. Merck & Co., Inc. UroGen Pharma, Inc.

Contemporary Management of MIBC and Beyond: Expert Guidance for Urologists CME Available: https://auau.auanet.org/node/42040 After participating in this CME activity, participants will be able to: 1. Describe the multimodal treatment approach for MIBC, including surgery, radiation therapy, and chemotherapy. 2. Analyze the role of neoadjuvant and adjuvant therapies, including chemotherapy, immunotherapy, and antibody drug conjugates, in improving patient outcomes. 3. Utilize knowledge of checkpoint inhibitors and antibody drug conjugates with their mechanisms of action to interpret the role of immunotherapy in the treatment of metastatic urothelial carcinoma. 4. Examine ongoing clinical trials and emerging treatments that are shaping the future of metastatic urothelial carcinoma management. 5. Employ appropriate patient and family education strategies regarding MIBC and metastatic urothelial carcinoma, treatment options, and expected outcomes. Acknowledgements Support provided by an independent educational grant from: Astellas and Pfizer, Inc.

Complex Cases in Kidney Stone Disease CME Available: https://auau.auanet.org/node/41889 At the conclusion of this activity, participants will be able to: 1. Describe the pathophysiology, genetic basis, and clinical presentation of Primary Hyperoxaluria Type 1. 2. Analyze the unique considerations and challenges in evaluating kidney stones in pediatric patients. 3. Utilize the results of 24-hour urine testing to guide dietary and pharmacologic interventions for stone prevention. 4. Recognize the indications for genetic testing in patients with kidney stones and utilize the results to inform diagnosis and treatment. 5. Employ appropriate patient management and family counseling strategies in consideration of the impact of genetic testing results. 6. Properly refer patients with kidney stone disease to a nephrologist when warranted. ACKNOWLEDGEMENTS: Support provided by an independent educational grant from:  Alnylam Pharmaceuticals, Inc.

Now in its 43rd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update24

AUA2024: Journal of Urology Lecture: Empowering Communities: Fostering Prostate Cancer Awareness and Resilience Among Men of Color Presenter: Quoc-Dien Trinh, MD, MBA

AUA2024: Ramon Guiteras Lecture: Modern Innovation: Promise or Peril? Presenter: Craig Niederberger, MD, FACS

AUA Leadership and Business Podcast: Urology Practice Manage - Overcoming Operational Challenges This episode is brought to you by the AUA Leadership and Business Podcast, where urologic professionals experience the practical application of business acumen essential to successfully navigating today's rapidly changing business environment! Subscribe today via your favorite podcast app.

Focal Therapy Options for Prostate Cancer AUA Urology Core Curriculum: auau.auanet.org/core Host: Jay D. Raman, MD, FACS, FRCS(Glasg) Guest: Ruben Olivares, MD Outline: Segment 1: Why Focal Therapy? Segment 2: Patient selection for Focal Therapy Segment 3: Review of Existing Focal Therapy Modalities Segment 4: How to Build a Successful Focal Therapy Program

Hereditary Kidney Cancer Syndromes CME Available: https://auau.auanet.org/node/41772 ACKNOWLEDGEMENTS: Support provided by an independent educational grant from:  Merck & Co., Inc.  LEARNING OBJECTIVES: At the conclusion of this activity, participants should be able to: 1. Select patients who should undergo genetic testing to identify hereditary kidney cancer syndromes based on appropriate criteria, including family history and clinical presentation. 2. Implement strategies to address ethical concerns related to genetic testing, such as patient consent, confidentiality, and the potential impact on family members. 3. Discuss VHL syndrome, including its genetic basis, inheritance pattern, and associated tumors. 4. Properly diagnose and manage VHL syndrome in clinical practice based on knowledge of novel therapeutic strategies. 5. Utilize a multidisciplinary approach consisting of urologists, oncologists, geneticists and nephrologists when managing hereditary kidney cancer syndromes.

Prostate Cancer Update (2024): Expert Guidance for Urologists CME Available: https://auau.auanet.org/node/41868 Acknowledgements Support provided by independent educational grants from: Astellas Lantheus Medical Imaging Novartis Pharmaceuticals Corporation Pfizer, Inc. Learning Objectives At the conclusion of this activity, the learner will: 1. Align their practice with current AUA Guidelines (and recent amendments) pertaining to Screening, Diagnosis, and Management of Prostate Cancer. 2. Determine appropriate use of biomarker testing as it relates to diagnosis and therapy. 3. Analyze the role of imaging and types of imaging that aid in staging patients with prostate cancer. 4. Implement appropriate treatment paradigms for metastatic prostate cancer including treatment intensification. 5. Discuss the role of genetic and molecular profiling in the personalization of prostate cancer treatment plans.

Treatment Intensification in Metastatic HSPC CME Available: https://auau.auanet.org/node/41733 ACKNOWLEDGEMENTS: Support provided by independent educational grants from:  Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Explain the rationale behind treatment intensification in metastatic hormone sensitive prostate cancer (mHSPC), based on its pathophysiology.  2. Analyze the rationale and clinical evidence supporting treatment intensification in mHSPC, including potential benefits and risks.  3. Select appropriate patients for treatment intensification, considering factors such as disease burden, patient comorbidities, and individual risk profiles.

Appropriate Use of Genetic Testing (who, what, when and how?) CME Available: https://auau.auanet.org/node/41734 ACKNOWLEDGEMENTS: Support provided by independent educational grants from:  Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Identify the patient populations that should be considered for genetic testing in prostate cancer, based on family history, personal risk factors, and clinical indications. 2. Integrate genetic testing into clinical practice for prostate cancer, including developing workflows, referral processes, and multidisciplinary collaboration. 3. Utilize genetic test results to inform personalized treatment plans for prostate cancer patients, including targeted therapies and risk reducing strategies.

Sequencing Of Agents CME Available: https://auau.auanet.org/node/41735 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Review the latest evidence and clinical guidelines that inform the sequencing of therapeutic agents in metastatic prostate cancer, including data from key clinical trials. 3. Implement strategies for managing and overcoming resistance to therapy in metastatic prostate cancer, considering the role of sequencing in delaying resistance. 4. Apply best practices for monitoring treatment response and disease progression in patients undergoing therapy, and adjust sequencing strategies based on these observations.

Urologic Oncology: Genetics And Genomics AUA Urology Core Curriculum: auau.auanet.org/core Host: Jay D. Raman, MD, FACS, FRCS(Glasg) Guest: Hong Truong, MD, MS Outline: Segment 1: Genetics 101 – How Genes Influence Cancer Risk Segment 2: Genetic Risk Assessment Segment 3: Genetics of Kidney Cancer Segment 4: Genetics of Upper Tract Cancer Segment 5: Genetics of Prostate Cancer

Biomarkers and Molecular Imaging for Prostate Cancer CME Available: https://auau.auanet.org/node/41727 ACKNOWLEDGEMENTS: Support provided by independent educational grants from:  Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Explain the principles of molecular imaging and its application in prostate cancer, including techniques such as PET, MRI, and novel radiotracers. 2. Evaluate recent advances in molecular imaging technologies and their role in improving the accuracy of prostate cancer diagnosis, staging, and treatment monitoring. 3. Define and classify different types of biomarkers relevant to prostate cancer, including diagnostic, prognostic, and predictive biomarkers.

Kidney Cancer & SBRT in the Management of RCC AUA Urology Core Curriculum: auau.auanet.org/core Host: Jay D. Raman, MD, FACS, FRCS(Glasg) Guest: Daniel Shapiro, MD Outline: Segment 1: History of radiation therapy in renal cell carcinoma Segment 2: Radiation use in the setting of primary kidney tumors Segment 3: Radiation use for locally advanced tumors including tumor thrombi Segment 4: Radiation therapy for metastatic disease Segment 5: Limitations of radiation therapy and selecting patients for radiation therapy

Pediatric Urology: Differences of Sex Development AUA Urology Core Curriculum: auau.auanet.org/core Host: Jay D. Raman, MD, FACS, FRCS(Glasg) Guest: Emilie Johnson, MD, MPH, FACS, FAAP Outline: Segment 1: DSD Nomenclature – Words Matter! Segment 2: Multidisciplinary Care Model Segment 3: Example Conditions Segment 4: Approach to Prenatal and Early Postnatal Care Segment 5: Gonadal Management – also evolving

How to use Prostate-Specific Membrane Antigen-Positron Emission Tomography/CT in the Management of Relapsing Prostate Cancer Patients following Local Therapy with Curative Intent CME Available: https://auau.auanet.org/node/41124 At the conclusion of this activity, participants will be able to: 1. Identify the clinical scenario in which PSMA PET/CT is most helpful to identify the localization and extent of locoregional or systemic metastatic disease. 2. Identify the pitfalls of false-positive and false-negative PSMA PET/CT findings. 3. Apply the findings of PSMA PET/CT for the best individual therapeutic approach. 4. Identify patients with radiorecurrent organ-confined prostate cancer. 5. Identify those patients who are candidates for local therapy of oligometastatic disease in relapsing prostate cancer. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.

The Changing Face of Advanced Prostate Cancer 2024 CME Available: https://auau.auanet.org/node/41136 At the conclusion of this activity, participants will be able to: 1. Identify and treat a patient with newly diagnosed M1 prostate cancer with androgen deprivation therapy plus be able to offer novel ADT. Furthermore, recognize high-volume new M1 prostate cancer so as to be able to refer to a genitourinary medical oncologist for chemotherapy if necessary. 2. Diagnose M0 CRPC, and be able to educate patients about using novel oral androgen receptor inhibitors added to traditional androgen deprivation therapy as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, understand the differences between these novel oral agents and educate patients about side effects and toxicities. Finally, understand the role or lack of role of prostate-specific membrane antigen PET in working up this disease state. 3. Apply the latest phase III randomized controlled trial results for new therapies in M1 CRPC, and be able to educate their patients on treatment options and work on a multidisciplinary team caring for this disease state of far advanced prostate cancer. 4. Identify that advanced prostate cancer is a complex group of disease states with a rapidly changing therapeutic landscape, and for providers and teams to embrace the multidisciplinary nature of care for our patients. 5. Identify the molecular and molecular genetic underpinnings of advanced prostate cancer and recognize the future will be based on a more personalized therapy landscape including PARP inhibition, immune checkpoint agents and novel androgen receptor-targeted agents emerging in 2024. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.

Now in its 43rd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update24

Prostate Cancer Diagnosis: AUA Guidelines on use of PSA Biomarkers, MRI and Biopsy Techniques CME Available: https://auau.auanet.org/node/41113 At the conclusion of this activity, participants will be able to: 1. Apply the Early Detection of Prostate Cancer: AUA/SUO Guideline (2023), and understand the rationale, evidence, level of evidence, strength of recommendation and applications associated with each statement. 2. Identify how to maximize the benefits and minimize the harms of prostate cancer detection by carefully selecting patients and by using the necessary tools to detect clinically significant prostate cancer, while avoiding unnecessary biopsies and detection of clinically insignificant prostate cancers. 3. Identify the evidence supporting the use of PSA for early detection of prostate cancer, and apply that evidence to different clinical scenarios, incorporating patient characteristics and preferences. 4. Identify available blood, urine and tissue biomarkers used to enhance detection of higher-grade prostate cancer, the evidence supporting their use, and the clinical scenarios in which they are most valuable to be used. 5. Use MRI and fusion biopsy to enhance the detection of clinically significant prostate cancer and implement safe biopsy practices with respect to approach, avoidance of infection, and attention to patient comfort; understand the rationale for transperineal prostate biopsy and its technique; be able to establish a transperineal biopsy practice. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.

Incorporating Genomic Testing and Advanced Imaging For Prostate Cancer Into Your Practice CME Available: https://auau.auanet.org/node/41033 At the conclusion of this activity, participants will be able to: 1. Identify the research that led to the approval of genomic cancer for prostate cancer and the implementation of advanced imaging for prostate cancer. 2. Order appropriate genomic testing and advanced imaging based on a patient's unique clinical situation. 3. State the National Comprehensive Cancer Network Guidelines for genomic testing and advanced imaging for prostate cancer. 4. Discern the different prognostic end points provided by various genomic tests. 5. Recognize candidates for, and implications of, germline testing for prostate cancer. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.

AUA2024: Upper Tract Urothelial Cancer (UTUC) Guidelines Upper Tract Urothelial Cancer (UTUC) Guidelines – An Interactive and Evidence-Based Course Highlighting the Full Spectrum of Disease via Case Discussion and Video Presentation CME Available: https://auau.auanet.org/node/41021 At the conclusion of this activity, participants will be able to: 1. Identify demographics, predisposing risks, hereditary factors, common terms. 2. Describe workup, imaging, role of standardized endoscopic assessment, cytology and biopsy. 3. Apply clinical features of disease risk, role of risk assessment and management options. 4. Identify candidates for endo management, describe counseling/risks, safe approaches, troubleshooting. 5. Explain setting and role for adjunctive chemotherapy use, importance of renal function, genetic counseling; describe approach to ureterectomy/bladder cuff, node dissection templates, intravesical therapy use; explain the rationale and use of risk-adjusted follow-up for endoscopy and imaging. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Merck & Co., Inc.

The Surgical Management of BPH and Updates from the AUA Clinical Guidelines Podcast (2024) CME Available: https://auau.auanet.org/node/41595 ACKNOWLEDGEMENT: This educational series is supported by an independent educational grant from Olympus Corporation of the Americas. At the conclusion of this activity, participants will be able to:   1. Describe the role of the AUA Clinical Guideline on the Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia. 2. Discuss the evidence base for current technologies, including pivotal studies, and be able to define the role and clinical expectation for each of them. 3. Interpret the current clinical results and compare the patient experiences of these treatments in relation to more established and even abandoned treatments for patient groups with similar characteristics. 4. Differentiate between each of the new technologies for treating BPH/LUTS based on both their mode-of-action and the quality of their supporting evidence.

New AUA Guideline (2024): Salvage Therapy for Prostate Cancer CME Available: https://auau.auanet.org/node/41074 At the conclusion of this activity, participants will be able to: 1. Identify and effectively interpret the optimal timing of salvage radiation therapy following radical prostatectomy, considering the factors that can influence this decision in a clinical context. 2. Develop an understanding of which patients should receive ADT alongside salvage radiation therapy following radical prostatectomy, and how to appropriately decide the duration of ADT for patients. 3. Identify and analyze the use of risk stratification tools and next-generation imaging techniques for guiding treatment decisions and monitoring in patients with biochemical recurrence following primary therapy. 4. Evaluate the role and benefits of advanced treatment options such as intensified systemic therapy and metastasis-directed therapy. 5. Evaluate and understand the indications, efficacy, and potential complications of different salvage local therapies, such as salvage prostatectomy, radiotherapy and cryotherapy, for patients with local recurrence following primary radiation therapy.

AUA2024: Genetics and Genomics of Urological Cancers - Current Guidelines and Case-based Discussion to Guide Clinical Practice CME Available: https://auau.auanet.org/node/40976 At the conclusion of this activity, participants will be able to: 1. Describe key components of genetic risk assessment, genetic counseling and informed consent for genetic testing. 2. Identify elements of genetic test reports including variant classification, variant allele frequency, gene penetrance, biomarkers and clinical actionability. 3. Identify criteria for genetic testing for men with prostate cancer. Understand the clinical implications of genetic result in prostate cancer screening and management of both localized and advanced prostate cancer. 4. Recognize genetic causes, tumor features, and cancer risk associated with Lynch syndrome, and apply gained knowledge to improve care of patients with upper tract urothelial carcinoma. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.

AUA2024: Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems CME Available: https://auau.auanet.org/node/41097 At the conclusion of this activity, participants will be able to: 1. Implement current practice guidelines and explain methods and resources to improve TURBT skills. 2. Identify the best intravesical agent and duration of therapy for low-, intermediate- and high-risk NMIBC and what to do during a BCG shortage. 3. Identify methods to treat significant toxicities from various intravesical therapies. 4. Define high-risk scenarios that necessitate cystectomy and options for BCG-unresponsive disease. 5. Identify the scientific rationale for investigating immune oncology agents for BCG-unresponsive disease and become familiar with current clinical trial designs. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Merck & Co., Inc.

AUA2024: Contemporary Pharmacotherapy for OAB 2024: Monotherapy and Combined Pharmacotherapy to Optimize Treatment CME Available: https://auau.auanet.org/node/41048 At the conclusion of this activity, participants will be able to: 1. Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB) 2. Review the principles of physiology and pharmacotherapy for currently available agents including the antimuscarinics and beta-3 agonists. 3. Review the salient features as well as changes in the updated AUA/SUFU guideline on OAB 4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents 5. Discuss potential future pharmacological pathways and therapies for OAB. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Astellas

AUA2024: AUA Advanced Prostate Cancer Guidelines CME Available: https://auau.auanet.org/node/41027 At the conclusion of this activity, participants will be able to: 1. Identify appropriate use of genetic testing and genetic counseling. 2. Identify appropriate use of somatic testing and treatments related to specific genetic alterations. 3. Identify appropriate combination therapy with androgen deprivation therapy plus novel androgen access therapies and chemotherapy. Early treatment intensification will be discussed in metastatic hormone-sensitive prostate cancer. 4. Identify the treatments for nonmetastatic CRPC and oncologic outcomes based on AUA/SUO (Society of Urologic Oncology) Guidelines. 5. Cancel patients on available treatment options for CRPC as well as combination therapy and sequencing based on AUA/SUO Guidelines. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.